newsfilter
← Latest News
GlobeNewswire·

NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer

Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026 ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- NovaBridge